Form 13-F position report

ADAGIO THERAPEUTICS INC

Reported by Slate Path Capital LP

IVVD CUSIP 00534A102 Manager CIK 0001559706

Reported 3,735,000 shares, unchanged from the prior quarter.

Reported value -37.2%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value 0.87% This manager · Q1 2022
Shares 3,735,000 Quarter-end amount reported
Reported value $17,032,000 Fair value at quarter end
Consecutive quarters held 2 Through Q1 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 27116000
2022-03-31 17032000
2022-06-30 12251000
2022-09-30 11691000
2022-12-31 5602500
2023-03-31 4482000
2023-06-30 3921750
2023-09-30 6349500
2023-12-31 14715900
2024-03-31 16583400
2024-06-30 4108500
2024-09-30 3809700
2024-12-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

13 quarters
Quarterly reported position history for ADAGIO THERAPEUTICS INC held by Slate Path Capital LP.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q4 2024 Reduced 0 -3,735,000 (-100.0%) 0 $0 2025-02-14
Q3 2024 Unchanged 3,735,000 0 (0.0%) 0.06% $3,809,700 2024-11-14
Q2 2024 Unchanged 3,735,000 0 (0.0%) 0.08% $4,108,500 2024-08-14
Q1 2024 Unchanged 3,735,000 0 (0.0%) 0.33% $16,583,400 2024-05-15
Q4 2023 Unchanged 3,735,000 0 (0.0%) 0.33% $14,715,900 2024-02-14
Q3 2023 Unchanged 3,735,000 0 (0.0%) 0.18% $6,349,500 2023-11-14
Q2 2023 Unchanged 3,735,000 0 (0.0%) 0.14% $3,921,750 2023-08-14
Q1 2023 Unchanged 3,735,000 0 (0.0%) 0.21% $4,482,000 2023-05-15
Q4 2022 Unchanged 3,735,000 0 (0.0%) 0.3% $5,602,500 2023-02-14
Q3 2022 Unchanged 3,735,000 0 (0.0%) 0.76% $11,691,000 2022-11-14
Q2 2022 Unchanged 3,735,000 0 (0.0%) 0.77% $12,251,000 2022-08-15
Q1 2022 Unchanged 3,735,000 0 (0.0%) 0.87% $17,032,000 2022-05-16
Q4 2021 New 3,735,000 +3,735,000 (0.0%) 1.42% $27,116,000 2022-02-14

Who else reported the position

98 managers reported ADAGIO THERAPEUTICS INC for Q1 2022.

Managers reporting ADAGIO THERAPEUTICS INC in Q1 2022.
Manager Activity Shares Change % of reported 13F Reported value Tenure
FMR LLC Reduced 15,233,378 -359,040 < 0.01% $69,464,203 3 qtrs
M28 Capital Management LP Added 6,398,250 +733,029 26.83% $29,176,000 2 qtrs
Alphabet Inc Unchanged 5,680,785 0 0.84% $25,904,000 3 qtrs
VANGUARD GROUP INC Added 5,324,126 +3,790,400 < 0.01% $24,278,000 3 qtrs
ORBIMED ADVISORS LLC Added 5,056,000 +72,500 0.38% $23,055,000 3 qtrs
Slate Path Capital LP This report Unchanged 3,735,000 0 0.87% $17,032,000 2 qtrs
BlackRock Inc Added 2,951,296 +1,644,029 < 0.01% $13,459,000 3 qtrs
683 Capital Management LLC Added 2,350,000 +1,730,000 0.57% $10,716,000 2 qtrs
Bain Capital Life Sciences Investors LLC Unchanged 1,937,207 0 0.86% $8,834,000 3 qtrs
Redmile Group LLC Unchanged 1,920,960 0 0.27% $8,760,000 3 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
March 31, 2022
Filed
May 16, 2022
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
3,735,000
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.